SCHEMBL13994580

SCHEMBL13994580

Cc1ccc(C(=O)c2nccn2C/C=C/c2ccc(CO[C@@H](C)C(=O)O)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 9/20 0.55
PPARA Q07869 8/20 0.55
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
OPRD1 P41143 1/20 0.35
TBXAS1 P24557 2/20 0.35
KDM5A P29375 1/20 0.33
KDM2B Q8NHM5 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
GRIK1 P39086 1/20 0.33
GRIK2 Q13002 1/20 0.33
MAOB P27338 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
PKM P14618 1/20 0.32
CYP2C19 P33261 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10151869 1.00 PPARG (0.55) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL13994388 0.91 PPARG (0.47) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL13994563 0.89 PPARG (0.63) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL13994505 0.87 PPARG (0.48) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL2973830 0.85 PPARG (0.47) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL2973831 0.85 PPARG (0.47) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL13994569 0.85 PPARG (0.39) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL13994595 0.84 PPARG (0.40) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL13994559 0.83 PPARG (0.67) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL2728814 0.83 PPARG (0.56) PPARGPPARANPC1RAB9AGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE DANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-11 US disclosed
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE DANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-11 US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE NR0B1, UGT1A10, NR0B2 PPARG 282/4885PPARA 411/4885NPC1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.